Xenon Pharmaceuticals Inc. — 2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022; filed March 1, 2023. The filing reports annual results, not a standalone 2022 fourth-quarter summary. Amounts are in U.S. dollars unless stated otherwise.
Business context
Xenon is a clinical-stage biopharmaceutical company focused on neurological disorders, particularly epilepsy. It had no products approved for sale and generated no product-sale revenue. Its lead proprietary candidate, XEN1101, was in Phase 3 development for focal onset seizures and primary generalized tonic-clonic seizures; it was also being studied in Phase 2 for major depressive disorder (MDD). XEN496 was in a Phase 3 pediatric trial for KCNQ2 developmental and epileptic encephalopathy (DEE). Neurocrine Biosciences was developing partnered candidate NBI-921352.
Key financial metrics
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $9.4 million | $18.4 million |
| Research and development expense | $105.8 million | $75.5 million |
| General and administrative expense | $32.8 million | $22.0 million |
| Operating loss | $129.1 million | $79.0 million |
| Net loss | $125.4 million | $78.9 million |
| Net loss per common share, basic and diluted | $2.06 | $1.77 |
| Net cash used in operating activities | $98.4 million | $69.5 million |
- Revenue was collaboration and licensing revenue, primarily from Neurocrine; the company had no product sales. The filing reports no meaningful product gross margin.
- At year-end, cash and cash equivalents were $57.2 million and marketable securities were $663.5 million, totaling $720.8 million. Total assets were $754.1 million; total liabilities were $32.6 million and consisted principally of lease liabilities and payables/accruals.
- No term-loan debt was outstanding at year-end; the Silicon Valley Bank term loan had been repaid in 2020. Operating lease liabilities were $10.4 million on the balance sheet; future minimum lease payments totaled $13.9 million.
- Financing activities provided $278.5 million in cash, largely from common-share and pre-funded-warrant issuance. Investing activities used $296.0 million, primarily reflecting net purchases of marketable securities.
Changes versus prior year
- Revenue fell $9.0 million, or about 49%, primarily as Neurocrine collaboration performance obligations and research services were completed, and because Pacira milestone revenue recorded in 2021 did not recur.
- Operating expenses rose $41.1 million, or about 42%. R&D increased $30.3 million, driven chiefly by XEN1101 Phase 3 activity and higher personnel and stock-based compensation; G&A increased $10.8 million.
- Net loss widened by $46.5 million, from $78.9 million to $125.4 million. Higher interest income partly offset the increased operating loss.
- Operating cash use increased by $28.9 million. Cash and cash equivalents declined from $175.7 million to $57.2 million, while marketable securities increased; total cash and securities rose from $551.8 million to $720.8 million.
Outlook, commentary, risks and unusual items
- Management expected year-end cash and marketable securities to fund operating and capital requirements for at least 12 months from the report date. The company anticipated continued significant losses and rising expenses; no revenue or earnings guidance was provided.
- Management anticipated XEN1101 MDD Phase 2 topline results in the third quarter of 2023, EPIK Phase 3 completion in 2024, and Neurocrine Phase 2 adult focal-seizure data in the second half of 2023. These are forward-looking expectations, not assured outcomes.
- In the X-TOLE Phase 2b focal-epilepsy trial, XEN1101 met its primary endpoint: median monthly seizure-frequency reductions were 52.8%, 46.4%, and 33.2% for 25 mg, 20 mg, and 10 mg, respectively, versus 18.2% for placebo. Adverse events were more frequent at higher doses; dizziness was reported in 31.6% of the 25 mg group versus 7.0% on placebo. Phase 3 outcomes remain uncertain.
- In November 2022, Pacira decided to stop clinical development of PCRX-301, a program licensed from Xenon; no Pacira milestone revenue was recorded in 2022.
- Neurocrine collaboration revenue concentration was significant: Neurocrine accounted for all reported 2022 revenue. Potential milestone and royalty receipts depend on the partner’s development and commercialization decisions and are not assured.
- Key risks include clinical-trial failure or delay, patient enrollment, regulatory approval, reliance on third-party manufacturers and collaborators, financing and dilution, intellectual-property protection, cybersecurity, foreign-exchange movements, and future pricing and reimbursement. Xenon reported no material legal proceedings. KPMG issued unqualified opinions on the financial statements and internal control over financial reporting.
Important facts for investors to verify
- Current XEN1101 Phase 3 enrollment, timing, safety findings, and eventual efficacy results relative to the Phase 2b X-TOLE data.
- Cash runway assumptions and subsequent cash use, including clinical-trial spending, share issuance, and the effect of any future financing or dilution.
- Progress and results for XEN496’s EPIK trial and XEN1101’s MDD study, including whether stated timelines remain current.
- Neurocrine’s progress with NBI-921352, the terms and status of future milestone opportunities, and any changes in collaboration priorities.
- Impact of the discontinued PCRX-301 program and any remaining obligations or recoverable value.